Merck & Co

Merck and Daiichi partner on a $5.5 billion deal for cancer therapy development

20 Oct 2023

The American pharmaceutical company Merck will start a joint venture with Daiichi Sankyo to develop three of its candidate cancer drugs.

AstraZeneca and Merck claim Japanese approval for anti-cancer drug Lynparza

20 Jun 2019

AstraZeneca and Merck in $8.5-billion oncology deal

27 Jul 2017

Merck calls off late-stage trial of Alzheimer’s drug verubecestat

15 Feb 2017

Merck wins $2.54 bn in royalties in patent lawsuit

16 Dec 2016

Merck & Co among five pharmaceutical companies in the race for Medivation

18 Aug 2016

Merck & Co and Allergan eye US biotechnology company Biogen

03 Aug 2016

Merck gets a $5-mn Ebola vaccine shot from Vaccine Alliance

22 Jan 2016

EU conditional nod for Merck's $17-bn purchase of Sigma-Aldrich

16 Jun 2015

Sigma-Aldrich is a life science and technology company that manufactures and distributes more than 230,000 chemicals, biochemicals and other essential products globally to research and applied labs as well as in industrial and commercial markets

Merck & Co to buy Cubist Pharmaceuticals for $8.4 bn

10 Dec 2014

Merck expects the acquisition to add more than $1 billion of revenue after closing in the first quarter, but will be neutral to non-GAAP earnings per share until 2016

Merck & Co in talks to buy Cubist Pharmaceuticals for more than $7 bn

06 Dec 2014

Cubist Pharmaceuticals develops drugs for potentially life-threatening infections caused by dangerous bacteria categorised as serious and urgent public health threats

Merck oncology drug wins ‘breakthrough’ classification by US regulators

28 Oct 2014

Keytruda, Merck & Co's flagship new drug, forms part of a new generation of oncology treatments that use the body’s own immune system to attack and destroy tumours

Merck & Co to sell some eye care products to Japan’s Santen Pharmaceutical for $600 mn

13 May 2014

Merck & Co to sell consumer care business to Germany's Bayer for $14.2 bn

06 May 2014

The deal, which will make Bayer the second-biggest over-the-counter drugs (OTC) maker after Johnson & Johnson, is the largest in the German healthcare industry after Bayer outbid Merck to acquire Schering in 2006 for $21.5 billion

Bayer offers to swap cash and animal health unit for Merck's consumer healthcare

30 Apr 2014

German healthcare major Bayer AG has offered to swap its animal health unit and also pay some cash in exchange for Merck & Co's consumer healthcare business

Bayer, Novartis, Reckitt Benckiser, P&G in fray for Merck & Co's consumer healthcare unit

20 Feb 2014

Bayer, Novartis, Reckitt Benckiser, and Procter & Gamble are among the companies that are exploring a deal to buy Merck &Co's consumer healthcare unit

Merck & Co agrees to pay $100 mn to settle NuvaRing contraceptive lawsuits

08 Feb 2014

Merck & Co mulls sale of consumer healthcare, animal health businessess

01 Feb 2014

Aspen Pharmacare to buy API business from Merck in $1 billion deal

27 Jun 2013

Merck & Co to buy back $5-bn worth stock

22 May 2013

Merck, the second-largest US drugmaker, will repurchase about 99.5 million shares from Goldman Sachs at current market prices

Delhi HC refuses interim relief to Merck over Glenmark drug

05 Apr 2013

Glenmark said the US drug firm has no patent rights over ‘Sitagliptin Phosphate’, which is used in its anti-diabetes drugs Zita and Zita-Met

Merck to pay $688 mn to settle anti-cholesterol drug Vytorin lawsuits

15 Feb 2013

Merck & Co forecast profit decline for 2013

02 Feb 2013

Merck to recall good HDL cholesterol drug Tredaptive

12 Jan 2013

Merck & Co in talks to buy Bangalore-based Micro Labs: report

21 Jun 2012